Long‐Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV‐Infected Patients with Undetectable Virus Load | Zendy

Paloma Gil | Zendy; Miguel Górgolas | Zendy; Vicente Estrada | Zendy; Alberto Arranz | Zendy; Pablo Rivas | Zendy; Carmen Yera | Zendy; Rosa García | Zendy; Juan José Granizo | Zendy; Manuel Fernández Guerrero | Zendy

Open Access

Long‐Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV‐Infected Patients with Undetectable Virus Load

Author(s) -

Paloma Gil,

Miguel Górgolas,

Vicente Estrada,

Alberto Arranz,

Pablo Rivas,

Carmen Yera,

Rosa García,

Juan José Granizo,

Manuel Fernández Guerrero

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/423385

Subject(s) - nevirapine , medicine , protease inhibitor (pharmacology) , viral load , virology , antiretroviral therapy , protease , term (time) , human immunodeficiency virus (hiv) , immunology , biology , enzyme , biochemistry , physics , quantum mechanics

Simplified highly active antiretroviral therapy (HAART) regimens are becoming widely used, particularly as a result of the side effects of and difficult compliance with protease inhibitor (PI) therapy. However, the long-term efficacy of HAART has not been properly assessed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research